logo重庆精准生物技术有限公司(Chongqing Precision Biotech Co., Ltd.)系国际先进精准医疗技术团队与国内知名上市公司联合投资的高新技术企业,总投资2.8亿元。目前公司已与国内外10多所顶级研究机构建立良好合作关系,并不断吸引国际著名的精准医学技术研究机构、高等院校前来合作,将最新的技术研究成果在公司孵化、转化和产业化。公司汇集了一批国际一流的精准医学领域专家及泰斗,围绕肿瘤、自身免疫性疾病、代谢性疾病和退行性疾病等影响人类健康的重大科学问题以基因测序、大数据分析的分子诊断技术、肿瘤疫苗、单克隆抗体、干细胞再生医学、靶点药物等精准医疗技术为切入点,开展个体化医疗与研究,完善生命科学研发价值链,服务于人类健康。

公司项目

公司秉承“科技引领,尊重生命”的理念,以肿瘤疫苗、单克隆抗体、CAR-T、TCR-T等生物治疗技术研发为核心业务,已相继与国内多家知名医院建立临床研究合作关系,取得显著疗效,获得广泛好评。

公司人才

公司拥有30多名高中级职称的科技研发和临床医疗团队,并聘任10余名国内外行业著名专家学者作为企业顾问团队,努力打造国际化、高水平、复合型人才团队;公司已相继与欧美多家国际顶尖院所达成战略合作关系,致力建设国内外精准医疗和生物治疗科研成果转化和产业化示范基地,引领产业发展。

公司使命

重庆精准生物技术有限公司寓意“精准”:我们恪守产品精确,服务精心,精确精心,精益求精;我们坚守技术准绳,做人准则,准绳法脉,四海皆准。

我们将秉承精诚合作的团队精神、严肃认真的科学态度,运用尖端高新的研究成果、扎实有效的临床经验,努力开拓精准医疗和生物治疗的新时代,实现繁衍绿色生命的夙愿和维护人类健康的梦想。

公司平台(Platform)


公司总部位于重庆市二郎高科创业园区内,建筑面积达6000平米,拥有符合GLP规范的基础研发平台,下设肿瘤疫苗研发中心、分子与病毒研发中心、细胞载体技术研发中心、抗体开发中心、体外细胞学功能评价中心、体内动物疗效评价中心等,共6大功能模块,并设有独立的技术临床转化平台,解决基础研发技术的标准化、规模化需求,衔接下游临床技术应用;临床应用方面,公司建设有2000平方米的cGMP临床产品生产制备平台,下设基因重组蛋白生产中心、临床级病毒载体生产中心、临床级质粒生产中心等,3大独立功能模块;此外,公司还建设有逾1000平方米的质控检测平台,下设基因诊断中心、细胞制品检测中心和生物样本库。

科研团队(Research Team)


公司“以人为本”的人才战略,汇聚了国内外生物治疗领域高尖端生物科技人才,公司研发团队中,硕士及博士高学历人才占比80%以上,核心岗位成员在精准医学领域有10年以上研究经验,具有扎实的理论基础和丰富的实践经验。团队成员已申请精准医疗领域相关专利10余项,在国际知名刊物发表论文数近百篇。公司及团队成员目前承担的国家及地方政府各类科研转化项目20余项,与美国、欧洲等国际多家顶尖院所达成战略合作关系,致力于建设国内外精准医疗科研成果转化和产业化示范基地,引领产业发展。

技术优势(Technical Advantage)


(1)引领时代进步的高新技术支持

拥有健全的基因组学和蛋白组学平台,引领肿瘤疫苗、单克隆抗体制备、NGS基因测序、大数据分析的分子诊断先进技术方向,掌握生物制药等核心技术。

(2)丰富的肿瘤相关基础研究经验和临床研究数据积累

长期致力于肿瘤基础研究,具有丰富的基础研究经验和丰富的临床研究数据,相关领域在国际学术界有很强的学术影响力。

(3)完善的基础研究成果转化机制

以基础到应用转化为导向,基础研究和临床治疗结合,形成了快速全方位的转化机制。

公司通过自主研发和技术引进,已拥有肿瘤疫苗、抗体高通量筛选和人源化改造、临床级质粒和慢病毒生产等先进生物技术。公司团队成员目前已授权和已公示的相关国家发明专利9项,实用新型专利12项。

Introduction of Chongqing Precision Biotech Co., Ltd

Chongqing Precision Biotech Co., Ltd. is a high and new technology company which jointly invested by an international advanced precision medical technology team and a domestic well-known listed company with total investment of 280 million RMB. It is also the transformation base of Ministry of Science and Technology’s National Center for International Joint Research on Precision Medicine and Biotherapy. At present, our company has already established good relationship with more than 10 top research institutions from domestic and overseas, and continues attracting international well-known precision medical technology research institutions as well as famous colleges. Closely cooperated with them, we could hatch, transform and industrialize the latest technology research results within the company.

1. High-end Research and Development Platform

Our company is headquartered in the High-tech Zone’s Hi-tech Startup Park of Chongqing, and built with the Chongqing Precision Biologic Industrial Technology Research Institute. With an area of 6,000 square meters and a basic R&D center which meets the GLP-standard, this research center has a total of 5 major functional modules: the molecular and virus research platform, the cell research and development platform, the antibody development platform, the in-vitro cellular function evaluation platform, the in vivo animal evaluation platform and etc..It also has an independent technology clinical translation platform to meet the needs for standardization and large-scale of our technologies, so as to link up the downstream clinical technology applications; in the aspect of clinical application, our company has built a cGMP clinical product production and preparation center with an area of 2,000 square meters. This centerhas3 major independent functional modules for production of the clinical-grade level of plasmids, lentivirus and cell productions, respectively. In addition, our company also has a quality management center with an area of 1,000 square meters which consist of the genetic diagnosis platform, cell products testing platform and a biological sample library.

2. Our Advanced Technical Advantages

Through independent research and development and technology introduction, our company now acquires the clinical level of cells, the plasmids and lentivirus production technology, the antibody high-throughput screening and humanization technology, the high memory CAR-T cell culture technology, the cancer stem cell targeting CAR-T cell technology, as well as the new immunosuppressive resistant CAR-T cell technology and other core technologies. We also focus on the development of allogeneic CAR-T cells, micro-environment-induced CAR-T cells and other new CAR-T technologies. Simultaneously, our company has also made a breakthrough in the field of TCR-T and CAR-NK technology. Our team members have already applied for more than 30 patents related to precision medical field, and have published more than100 SCI papers on internationally renowned publications.

Under the strict implementation, our company’s research and development platforms have designed and established according with the guidelines and standards of the national GLP and GMP, and now we have established 5 major research and development and clinical application platforms: the Immune Cell Therapy Technology Basic Research and Development Platform ,the Immune Cell Therapy Products GMP Preparation Platform, the Clinical-grade Plasmid GMP Preparation Platform, the Clinical-grade Lentivirus GMP Preparation Platform and the Quality Control and Sample Library Platform. Through the establishment of a sound quality control system and standardized operating procedures (SOP), we can ensure the company’s product safety and effectiveness.

3. An International Team of Experts

Our company and team members are currently in charge of more than 20scientific research and transformation projects which are all appointed by the national and local governments. We have established the strategic cooperation relationship with Charité-Universitätsmedizin Berlin of German, the University of Texas MD Anderson Cancer Center, the University of Navarra of Spain and many other top international institutions and have formed an exchange mechanism for international experts and domestic talents. We commit to the construction of an international center for precision medical research and translational medicine.Our company pursues the “people-oriented” talent strategy and brings the top biotechnology talents from domestic and overseas in the field of biological treatment together. We now have an  R&D team with more than 80 members, including master's and doctoral highly educated researchers accounted for more than 80%. Core researchers of the team are all have more than 10-yearresearch experience in precision medicine, so they have solid theoretical foundation and rich practical experience.

4. The Perfect Industrial Layout

Our company follow the national “innovation-driven” development strategy, takes benefiting the entire citizen by health technology as its goal and facilitates the rapid development of precision medical and biological industries as its focus. We set the layout of precision medical scientific discovery, technological invention, industrial development of the entire research and development chain; we invest and establish biological sample bank, biological information analysis platform, gene detection platform, gene editing and screening platform, cell preparation platform, biological medicine pilot platform, testing platform, health management center, clinical treatment center and other research and development platform as well. We are now developing the whole industry chain of precision medical biological resources storage, genetic diagnosis, gene editing, bio-pharmaceutical, health management and clinical treatment as well.